COVID-19 Treatment at a Glance

Arikan H., KARADOĞAN D., Tokgöz Akyıl F., YÜKSEL A., TÖREYİN Z. N., GÜNDÜZ GÜRKAN C., ...Daha Fazla

Turkish Thoracic Journal, cilt.21, sa.6, ss.438-445, 2020 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 21 Sayı: 6
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/turkthoracj.2020.20125
  • Dergi Adı: Turkish Thoracic Journal
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.438-445
  • Anahtar Kelimeler: Coronavirus disease 2019, treatment, hydroxychloroquine, tocilizumab, convalescent plasma, OXYGEN-THERAPY, NASAL CANNULA, CORONAVIRUS, INTUBATION, PNEUMONIA, EFFICACY, ANAKINRA, INJURY, SARS
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Evet

Özet

As coronavirus disease 2019 (COVID-19) spreads across the world, the ongoing clinical trials are leading to a big race worldwide to develop a treatment that will help control the pandemic. Unfortunately, COVID-19 does not have any known effective treatment with reliable study results yet. In this pandemic, there is not a lot of time to develop a new specific agent because of the rapid spread of the disease. The process of developing a vaccine is long and requires hard work. Although the pathophysiology of the disease is not fully understood, some of the proposed treatment alternatives are based on old evidence and some have been used with the idea that they might work owing to their mechanism of action. The efficacy, reliability, and safety of the currently available treatment alternatives are therefore a matter of debate. Currently, the main therapies used in the treatment of COVID-19 are antiviral drugs and chloroquine/hydroxychloroquine. Other proposed options include tocilizumab, convalescent plasma, and steroids, but the mainstay of the treatment in intensive care units remains supportive therapies.